A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

NCT IDNCT06984341ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 1

Ages

18–75

Locations

2 sites in AL, IA

What this study is about

This Phase 1 study is testing Cyclophosphamide in people with systemic lupus erythematosus. The primary outcome being measured is Number of Participants With Adverse Events (AEs).

Simplified from trial records by PatientMatch.

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Injection / IV

How treatment is administered

Treatment Assignment

Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine

Drug routes

infusion

Endpoints

Primary: Number of Participants With Adverse Events (AEs)

Body systems

Immune

Screen for this study View on ClinicalTrials.gov